BACKGROUND: Roux-en-Y gastric bypass (RYGBP) powerfully reduces type 2 diabetes (T2DM) incidence. Proinsulin predicts development of T2DM. Adjustable gastric banding is associated with lowered proinsulin but after RYGBP information is scant. METHODS: Twenty-one non-diabetic morbidly obese patients who underwent RYGBP surgery were evaluated before (baseline), at 12 months (first follow-up), and at 42 months, range 36-50 (second follow-up), after surgery and compared to a control group, matched at baseline regarding fasting glucose, insulin, proinsulin, alanine aminotransferase (ALT), high-density lipoprotein (HDL) cholesterol, and body mass index (BMI). RESULTS: In the RYGBP group, fasting serum proinsulin concentrations were markedly lowered from 13.5 to 3.5 pmol/l at first follow-up and to 4.9 pmol/l at second follow-up (p < 0.001, respectively). Fasting insulin concentrations were reduced from 83.4 to 24.6 pmol/l at first follow-up (p < 0.001) and to 36.4 pmol/l at second follow-up (p < 0.01). ALT was lowered from 0.62 to 0.34 mukatal/l at first follow-up and continued to lower to 0.24 mukatal/l at second follow-up (p < 0.001, respectively). The further decrease between first and second follow-up was also significant (p = 0.002). HDL cholesterol increased from 1.16 to 1.45 mmol/l at the first follow-up and continued to increase at second follow-up to 1.58 mmol/l (p < 0.001, respectively). The further increase between first and second follow-up was also significant (p = 0.006). The differences between groups at first follow-up were significant for BMI, proinsulin, insulin, ALT, and HDL cholesterol (p = 0.04-0.001). CONCLUSION: RYGBP surgery in morbidly obese patients is not only characterized by markedly and sustained lowered BMI but also lowered concentrations of proinsulin, insulin, and ALT and increased HDL cholesterol.
BACKGROUND: Roux-en-Y gastric bypass (RYGBP) powerfully reduces type 2 diabetes (T2DM) incidence. Proinsulin predicts development of T2DM. Adjustable gastric banding is associated with lowered proinsulin but after RYGBP information is scant. METHODS: Twenty-one non-diabetic morbidly obesepatients who underwent RYGBP surgery were evaluated before (baseline), at 12 months (first follow-up), and at 42 months, range 36-50 (second follow-up), after surgery and compared to a control group, matched at baseline regarding fasting glucose, insulin, proinsulin, alanine aminotransferase (ALT), high-density lipoprotein (HDL) cholesterol, and body mass index (BMI). RESULTS: In the RYGBP group, fasting serum proinsulin concentrations were markedly lowered from 13.5 to 3.5 pmol/l at first follow-up and to 4.9 pmol/l at second follow-up (p < 0.001, respectively). Fasting insulin concentrations were reduced from 83.4 to 24.6 pmol/l at first follow-up (p < 0.001) and to 36.4 pmol/l at second follow-up (p < 0.01). ALT was lowered from 0.62 to 0.34 mukatal/l at first follow-up and continued to lower to 0.24 mukatal/l at second follow-up (p < 0.001, respectively). The further decrease between first and second follow-up was also significant (p = 0.002). HDL cholesterol increased from 1.16 to 1.45 mmol/l at the first follow-up and continued to increase at second follow-up to 1.58 mmol/l (p < 0.001, respectively). The further increase between first and second follow-up was also significant (p = 0.006). The differences between groups at first follow-up were significant for BMI, proinsulin, insulin, ALT, and HDL cholesterol (p = 0.04-0.001). CONCLUSION: RYGBP surgery in morbidly obesepatients is not only characterized by markedly and sustained lowered BMI but also lowered concentrations of proinsulin, insulin, and ALT and increased HDL cholesterol.
Authors: J M Kellum; J F Kuemmerle; T M O'Dorisio; P Rayford; D Martin; K Engle; L Wolf; H J Sugerman Journal: Ann Surg Date: 1990-06 Impact factor: 12.969
Authors: Naveed Sattar; Alex McConnachie; Ian Ford; Allan Gaw; Stephen J Cleland; Nita G Forouhi; Peter McFarlane; James Shepherd; Stuart Cobbe; Chris Packard Journal: Diabetes Date: 2007-04 Impact factor: 9.461
Authors: Ignacio Garcia-Marirrodriga; Cesar Amaya-Romero; Gabriel Patiño Ruiz-Diaz; Sandra Férnandez; Carlos Ballesta-López; Jose M Pou; June H Romeo; Gemma Vilahur; Gemma Vilhur; Lina Badimon; Juan Ybarra Journal: Obes Surg Date: 2012-04 Impact factor: 4.129
Authors: G Rega-Kaun; C Kaun; G Jaegersberger; M Prager; M Hackl; S Demyanets; J Wojta; P J Hohensinner Journal: Obes Surg Date: 2020-02 Impact factor: 4.129
Authors: Hans-Erik Johansson; Arvo Haenni; F Anders Karlsson; Britt Edén-Engström; Margareta Ohrvall; Magnus Sundbom; Björn Zethelius Journal: Obes Surg Date: 2010-05 Impact factor: 4.129
Authors: Maria Antonella Burza; Stefano Romeo; Anna Kotronen; Per-Arne Svensson; Kajsa Sjöholm; Jarl S Torgerson; Anna-Karin Lindroos; Lars Sjöström; Lena M S Carlsson; Markku Peltonen Journal: PLoS One Date: 2013-03-26 Impact factor: 3.240